Alteration in the gut microbiota has been proposed in irritable bowel syndrome (IBS) pathogenesis, especially in the diarrheal type (IBS-D). We conducted this study to evaluate the fecal microbiota in Thai IBS-D patients when compared with healthy subjects as well as to evaluate the effects of probiotics on changes in the gut microbiota correlated with symptoms. A matched case–control study was conducted on diagnosed IBS-D patients, based on the Rome IV criteria and healthy controls. Stool samples were collected in preservation tubes. Bacterial deoxyribonucleic acid extraction was performed and amplified. Next, 16S ribosomal ribonucleic acid genes sequencing was performed to identify the microbiome in both the groups. IBS-D patients were provided with a probiotic mixture that was rich in Lactobacillus acidophillus and Bifidobacterium bifidum over 8 weeks. Changes in the symptoms, stool characteristics, and fecal microbiota were evaluated and compared with the corresponding baseline values. Twenty IBS-D patients with 20 age and gender-matched controls were included in this study. The baseline characteristics were not significantly different between the groups, including the mode of birth and the history of breastfeeding in infancy. No significant difference was noted in the fecal microbiota between the IBS-D patients and controls. The IBS symptom severity scales (IBS-SSS) were not statistically different after probiotic prescription; although, the bowel movements, the sense of urgency to go to the toilet and passing of mucous stool had obviously decreased. No change was noted in the fecal microbiota after receiving the experimental probiotic, except for an increase in the proportion of B. bifidum. Alteration in the gut microbiota composition was probably not the main pathogenic mechanism in the Thai IBS-D patients assessed in this study. However, modifying microbiomes with potentially protective bacteria seems to be a beneficial therapy. Thai Clinical trial registry: TCTR20191211006, Date of registration: 10 Dec 2019. Retrospectively registered, Clinical trial URL: www.clinicaltrials.in.th

中文翻译：

---

腹泻型肠易激综合征与健康受试者之间的肠道菌群没有区别：泰国的病例对照研究

在肠易激综合征（IBS）的发病机理中，尤其是在腹泻型（IBS-D）中，提出了肠道菌群的改变。我们进行了这项研究，以评估泰国IBS-D患者与健康受试者相比的粪便微生物群，以及评估益生菌对肠道肠道菌群与症状相关变化的影响。根据罗马IV标准和健康对照，对确诊的IBS-D患者进行了匹配的病例对照研究。粪便样品收集在保存管中。进行细菌脱氧核糖核酸提取并扩增。接下来，进行16S核糖体核糖核酸基因测序以鉴定两组中的微生物组。向IBS-D患者提供了在8周内富含乳酸杆菌和双歧双歧杆菌的益生菌混合物。评估症状，粪便特征和粪便微生物群的变化，并将其与相应的基线值进行比较。这项研究包括20名年龄与性别匹配的20名IBS-D患者。两组之间的基线特征无显着差异，包括出生方式和婴儿期的母乳喂养史。在IBS-D患者和对照组之间，在粪便菌群中没有发现显着差异。服用益生菌后，IBS症状严重程度量表（IBS-SSS）无统计学差异。虽然排便，上厕所的紧迫感和粘液粪便的通过明显减少。接受实验性益生菌后，粪便菌群无任何变化，只是双歧杆菌的比例有所增加。在这项研究中评估的泰国IBS-D患者中，肠道菌群组成的改变可能不是主要的致病机制。但是，用潜在的保护性细菌修饰微生物组似乎是一种有益的疗法。泰国临床试验注册中心：TCTR20191211006，注册日期：2019年12月10日。回顾性注册，临床试验网址：www.clinicaltrials.in.th 用潜在的保护性细菌修饰微生物组似乎是一种有益的疗法。泰国临床试验注册中心：TCTR20191211006，注册日期：2019年12月10日。回顾性注册，临床试验网址：www.clinicaltrials.in.th 用潜在的保护性细菌修饰微生物组似乎是一种有益的疗法。泰国临床试验注册中心：TCTR20191211006，注册日期：2019年12月10日。回顾性注册，临床试验网址：www.clinicaltrials.in.th